|
⚲
|
| Keyboard |
| DSC Advisors LP
✚
|
|
|---|---|
| CRD # | 158312 |
| SEC # | 801-73330 |
| CIK # | 0001299434 |
| AUM | |
| Employees | 8 (62% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 312-915-2400 |
| Address | 900 N Michigan Ave Chicago, IL 60611 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (1/3/2020) [Brochure] |
|---|
Item 5 – Fees and Compensation Management Fees; Performance-Based Compensation We generally receive a management fee calculated as a fixed percentage of the value of the assets we manage. In addition, and as further described in Item 6, we or our affiliates are entitled to additional compensation in the form of an incentive allocation based on the performance achieved for a client over a specified measurement period, generally, a fiscal year (collectively, the management fee and incentive allocation, if applicable, are referred to herein as “Fees”). Our Fees are deducted from the Funds’ assets. Our fee schedule is omitted since this brochure is only delivered to qualified purchasers as defined in Section 2(a) (51) (A) of the Investment Company Act of 1940, as amended. Fees applicable to the Funds are described in each Fund’s applicable offering documents. With regard to any of the Fees, we are generally permitted under the terms of a Fund’s governing documents to reduce or waive, in our sole discretion, our Fees for underlying investors in any of the Funds. For example, we can reduce the Fees applicable to investments in any of the Funds by certain large, strategic, or affiliated investors. For the year ended December 31, 2018, we have waived certain components of the Fees for certain affiliated investors. We can launch or manage other funds or accounts with higher or lower fees and/or different compensation structures. To the extent the Fund invests in any affiliated funds, the Fund will receive the benefit of any appropriate management fee offsets. Different client facts and circumstances, including the client’s investment strategy, liquidity profile and prevailing market terms, will be considered in determining applicable Fees. Costs and Expenses In addition to the Fees discussed above, investors in the Funds will bear indirectly the fees and expenses charged to the Funds. While those fees will vary, they typically include, but are not limited to the following: the Feeder Fund’s applicable pro rata portion of the Master Fund’s expenses relating to its investment activities, including brokerage commissions, prime brokerage fees, “bid-ask” spreads, mark-ups, interest expenses, stock loan expenses, costs incurred by errors committed in trading securities barring willful misconduct, gross negligence, or bad faith and other transactional charges. The Funds also will directly bear certain expenses relating to cash management and certain administrative costs, such as legal, accounting, audit, tax preparation, consulting and custodial fees and expenses. The Feeder Fund’s offering and governing documents detail the costs and expenses that are the responsibility of the applicable Fund, as well as certain overhead costs and expenses that generally are our responsibility. |
| Account Minimums and Types of Clients — Form ADV Part 2A (1/3/2020) [Brochure] |
|---|
Item 7 – Types of Clients The Adviser currently provides discretionary investment advice to several related private investment funds, including private investment partnerships and foreign investment companies. Interests in the Funds are offered pursuant to applicable exemptions from registration under the Securities Act of 1933, as amended. Investors in the Funds are subject to qualification standards. Investors in the Funds may include, among others, pension plans, foundations, funds of funds, family offices, trusts, other institutional investors and high net worth individuals. The minimum initial investment in the Funds is generally $1 million, subject to change or waiver at the discretion of the Adviser and/or the Fund’s Board of Directors, if applicable. In addition to the Funds, we could in the future provide advisory services to other private investment funds or other clients. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Ehealth Inc | 2.4 | ||
| Kornit Digital Ltd | 1.5 | ||
| Menlo Therapeutics Inc | 1.3 | ||
| Facebook Inc | 0.6 | ||
| Microsoft Corp | 0.5 | ||
| Alphabet Inc | 0.5 | ||
| Mastercard Inc | 0.4 | ||
| Visa Inc | 0.4 | ||
| Netflix Inc | 0.4 | ||
| Oracle Corp | 0.3 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | DSC Pe/VC Index Fund LP | [2016-11-03] | 5.1 M | 5.0 M |
| Filed 2021-04-07 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Commission $38,429 · Net Assets Decline to Disclose | ||||
| HF | DSC Thomson Reuters PE Index Master Fund LP | [2014-03-28] | 5.3 M | 14.9 M |
| Filed 2021-04-07 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | DSC Thomson Reuters VC Index Master Fund LP | [2013-03-25] | 10.8 M | 17.1 M |
| Filed 2026-03-04 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Delaware Street Capital Master Fund LP | 2012-02-10 | 380.9 M | |
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 2 | 380.9 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 2 | 380.9 |
| By Discretionary | ||
| Discretionary | 2 | 380.9 |
| Non-Discretionary | 0 | 0.0 |
| Total | 2 | 380.9 |
| By Non-United States Persons | ||
| Non-United States Persons | 234.8 | |
| United States Persons | 146.1 | |
| Total | 2 | 380.9 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Andrew Bluhm | Executive Officer | 10 | 3 | |
| David Nietfeldt | Executive Officer | 6 | 3 | |
| Arthur Bushonville | Executive Officer | 3 | 2 | |
| Dsc QG Partners LLC | Executive Officer | 3 | 2 | |
| Steve Bohn | Executive Officer | 3 | 2 | |
| Amy Close | Executive Officer | 3 | 2 | |
| Dscqg PR LLC | Executive Officer | 3 | 2 | |
| Jeffrey Knupp | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001299434] | |
| 3 | [0001299434] | |
| 4 | [0001299434] | |
| SC 13D | [0001299434] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| DSC Advisors LP | BioScrip Inc | [2014-12-30] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.2B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Zevra Therapeutics Inc KMPH
Common Stock, par value $0.0001
|
2018-10-05 | Buy | 2,000,000 | $3.00 | 6,000,000 |
|
Zevra Therapeutics Inc KMPH
Common Stock, par value $0.0001
|
2018-07-30 | Buy | 304,283 | $4.00 | 1,217,132 |
|
Zevra Therapeutics Inc KMPH
Common Stock, par value $0.0001
|
2017-09-14 | Buy | 138,857 | $3.30 | 458,228 |
|
Zevra Therapeutics Inc KMPH
Common Stock, par value $0.0001
|
2017-09-13 | Buy | 186,831 | $3.25 | 607,201 |
|
Zevra Therapeutics Inc KMPH
Common Stock, par value $0.0001
|
2017-09-13 | Buy | 200 | $3.25 | 650 |
|
Neos Therapeutics Inc NEOS
Series C Preferred Stock · derivative
|
2015-07-28 | Conversion | 34,153 | ||
|
Neos Therapeutics Inc NEOS
Preferred Stock Warrant (Right to Buy) · derivative
|
2015-07-28 | Option exercise | 170,766 | ||
|
Neos Therapeutics Inc NEOS
Series C Preferred Stock · derivative
|
2015-07-28 | Conversion | 1,496,521 | ||
|
Neos Therapeutics Inc NEOS
Series B-1 Preferred Stock · derivative
|
2015-07-28 | Conversion | 493,982 | ||
|
Neos Therapeutics Inc NEOS
Series B Preferred Stock · derivative
|
2015-07-28 | Conversion | 153,009 | ||
|
Neos Therapeutics Inc NEOS
Common Stock
|
2015-07-28 | Conversion | 205,825 | ||
|
Neos Therapeutics Inc NEOS
Common Stock
|
2015-07-28 | Conversion | 623,550 | ||
|
Neos Therapeutics Inc NEOS
Common Stock
|
2015-07-28 | Conversion | 14,230 | ||
|
Neos Therapeutics Inc NEOS
Common Stock
|
2015-07-28 | Conversion | 63,753 |